Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate: an Interventional, Multicenter, Prospective, Open-label, Single-arm Clinical Trial With Clinical, Ultrasound and Biomarker Assessments

NCT05121298 is registered in ClinicalTrials.gov with Atsushi Kawakami as lead sponsor.

NCT NCT05121298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05121298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate: an Interventional, Multicenter, Prospective, Open-label, Single-arm Clinical Trial With Clinical, Ultrasound and Biomarker Assessments
Lead sponsor
Atsushi Kawakami
Phase
Phase 3
Overall status
Unknown status
Start date
January 12, 2021
Completion date
September 30, 2024
Enrollment
155 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, jak inhibitor, musculoskeletal ultrasound, rheumatoid arthritis